Sign In
Buy OTLK
$0.98
-0.0634 (-6.10%)
At Close: Jul 31, 2026
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
04:11am, Monday, 26'th Aug 2024
Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
07:05am, Wednesday, 14'th Aug 2024
ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
09:05am, Monday, 12'th Aug 2024
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
09:10am, Tuesday, 30'th Jul 2024
Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
07:12am, Thursday, 11'th Jul 2024
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps i
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
08:35am, Monday, 08'th Jul 2024
ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab
Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
07:38am, Wednesday, 19'th Jun 2024
It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical factors such as float size and short interest. While the b
Outlook Therapeutics: Worth A Good Strong Look After CRL
05:22pm, Thursday, 13'th Jun 2024
Outlook Therapeutics received a Complete Response Letter from the FDA in August 2023, causing a 74% drop in share price. Following a Type A meeting with the FDA in November 2023, Outlook agreed to con
Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market
05:50am, Thursday, 13'th Jun 2024
Outlook Therapeutics is resubmitting a BLA for ONS-5010 by 2024, with top-line data expected in Q4, 2024. ONS-5010 received European Commission Marketing Authorization for treating wet AMD in May 2024
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
10:00am, Wednesday, 12'th Jun 2024
Live webcast on Thursday, June 13th at 4:00 PM ET FRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announc
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
09:05am, Tuesday, 11'th Jun 2024
ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevaciz
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
10:30am, Thursday, 06'th Jun 2024
Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commiss
ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizu
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
02:35pm, Thursday, 16'th May 2024
Outlook Therapeutics, Inc. (NASDAQ:OTLK ) Q2 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Russell Trenary - President & CEO Lawrence Ken
